Literature DB >> 20561303

Trimethoprim-sulfamethoxazole-induced rhabdomyolysis in an allogeneic stem cell transplant patient.

P J Kiel1, N Dickmeyer, J E Schwartz.   

Abstract

Trimethoprim-Rhabdomyolysis is a serious, potentially life-threatening complication diagnosed when creatine phosphokinase levels exceed 1000 U/L. Although many drugs are associated with rhabdomyolysis, the previous reports of trimethoprim-sulfamethoxazole (TMP/SMX)-induced rhabdomyolysis have involved patients with human immunodeficiency virus/acquired immunodeficiency syndrome. This is the first report, to our knowledge, of TMP/SMX-induced rhabdomyolysis in an allogeneic stem cell transplant patient.
© 2010 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20561303     DOI: 10.1111/j.1399-3062.2010.00524.x

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN: 1398-2273            Impact factor:   2.228


  4 in total

1.  Increased Rates of Rhabdomyolysis in Male Hematopoietic Cell Transplantation Recipients Taking Sirolimus and Trimethoprim/Sulfamethoxazole.

Authors:  Jeffrey Lew; Courtney D Fitzhugh; John F Tisdale; Matthew M Hsieh
Journal:  Transplant Cell Ther       Date:  2021-08-19

2.  Rhabdomyolysis in a Patient with Severe Hypothyroidism.

Authors:  Nooshin Salehi; Endre Agoston; Iqbal Munir; Gary J Thompson
Journal:  Am J Case Rep       Date:  2017-08-22

3.  Rhabdomyolysis due to Trimethoprim-Sulfamethoxazole Administration following a Hematopoietic Stem Cell Transplant.

Authors:  Alexander Augustyn; Mona Lisa Alattar; Harris Naina
Journal:  Case Rep Oncol Med       Date:  2015-10-18

4.  Rash and elevated creatine kinase in a deployed soldier.

Authors:  Thomas W Schmidt; Mark Garfinkle; Daniel F Battafarano
Journal:  Mil Med       Date:  2014-02       Impact factor: 1.437

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.